Stay Informed
Medical Links
- 2010 Alzheimer's Disease Facts and Figures - updated facts for 2010 on AD
- Abbott Laboratories
- Adult Care Advisors
- Alcoeur Gardens - Special care for the Alzheimer’s Disease patient
- Alzheimer’s Disease information provided by Novartis Pharmaceuticals - For patients and caregivers
- Alzheimer’s Foundation of America
- Alzheimer’s Foundation of America - Support resource for patients, cargivers and health care professionals
- Alzheimer’s Disease Clinical Trials
- Bristol-Myers Squibb Prodromal AD study
- CLINICAL RESEARCH TRIALS IN ALZHEIMER'S DISEASE - All current AD trials in the United States
- Clinical Trials at Memory Enhancement Centers of America - Clinical Research Trials
- COVANCE
- Dr Danov : Neuropsychologist PC - Pediatric and Adult Neuropsychology
- Eisai
- Elan Corporation
- Geriatric Medical Center of Dr. Sanjiv, Sharma, MD - First class geriatric medical care for seniors
- ICON Central Laboratories
- Lori Wright Consulting - CNS research consulting firm
- Neuronascent
- Novartis
- Pfizer
- Quintiles
- Sanofi-Aventis
- The Regency at Dover (Toms River, NJ) - “A Premier Senior Club”
- Wyeth Pharmaceuticals
Links
Search
 |
Joel S. Ross, MD |
MD FACP AGSF CMD CPI |
President and Founder |
Memory Enhancement Center |
of America, Inc. |
4 Industrial Way West, 2nd Floor |
Eatontown, New Jersey 07724 |
732.571.1535 |
Bristol-Myers Squibb-CN156-018: A Phase 2 study evaluating an investigational drug called BMS-708163, compared to placebo in persons with Prodromal Alzheimer’s Disease . This study is seeking participants with Prodromal Alzheimer’s between the ages of 45-90. The study will last about 1 year
Janssen ELN115727-301
A Phase 3 study evaluating an investigational drug called Bapineuzumab, compared to placebo in persons with Alzheimer’s Disease who are Apolipoprotein Ee4 non-carriers . This study is seeking participants with Mild to Moderate Alzheimer’s between the ages of 50-88 willing to participate in the Lumbar Puncture sub-study. The study will last about 18 months
Janssen ELN115727-302
A Phase 3 study evaluating an investigational drug called Bapineuzumab, compared to placebo in persons with Alzheimer’s Disease who are Apolipoprotein Ee4 carriers . This study is seeking participants with Mild to Moderate Alzheimer’s between the ages of 50-88 who are willing to participate in the Lumbar Puncture sub-study. The study will last about 18 months
Wyeth 3134K1-2201-US
A Phase 2A study evaluating an investigational drug called ACC-001 and QS-21, compared to placebo in persons with Alzheimer’s Disease . This study is seeking participants with Mild to Moderate Alzheimer’s between the ages of 50-85. The study will last about 18 months
Wyeth 3133K1-3001
A Phase 3 study evaluating an investigational drug called Bapineuzumab, compared to placebo in persons with Alzheimer’s Disease who are Apolipoprotein Ee4 carriers. This study is seeking participants with Mild to Moderate Alzheimer’s between the ages of 50-88. The study will last about 20 months
Novartis CENA713DUS44
A Phase 4 study evaluating an investigational drug called ENA713D Exelon (Rivastigmine Patch) in persons with Alzheimer’s Disease. This study is seeking participants with Severe Dementia of the Alzheimer’s Type who are 50 years of age and above. The study will last about 24 Weeks
Roche WN22018
A Phase 2B study evaluating an investigational drug called R05313534 in addition to Donepezil, compared to placebo in persons with Alzheimer’s Disease. This study is seeking participants with Mild to Moderate Alzheimer’s between the ages of 50-85. The study will last about 24 Weeks